Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Atea Pharmaceuticals (AVIR) EBITDA (2020 - 2022)

Atea Pharmaceuticals (AVIR) has 3 years of EBITDA data on record, last reported at -$34.3 million in Q4 2022.

  • For Q4 2022, EBITDA fell 129.25% year-over-year to -$34.3 million; the TTM value through Dec 2022 reached -$116.6 million, down 186.8%, while the annual FY2025 figure was -$158.4 million, 5.91% up from the prior year.
  • EBITDA reached -$34.3 million in Q4 2022 per AVIR's latest filing, down from -$8.9 million in the prior quarter.
  • Across five years, EBITDA topped out at $117.1 million in Q4 2021 and bottomed at -$42.1 million in Q1 2022.
  • Average EBITDA over 3 years is $558666.7, with a median of -$9.5 million recorded in 2020.
  • Peak YoY movement for EBITDA: soared 857.85% in 2021, then tumbled 460.71% in 2022.
  • A 3-year view of EBITDA shows it stood at $20.6 million in 2020, then skyrocketed by 467.31% to $117.1 million in 2021, then plummeted by 129.25% to -$34.3 million in 2022.
  • Per Business Quant database, its latest 3 readings for EBITDA were -$34.3 million in Q4 2022, -$8.9 million in Q3 2022, and -$31.3 million in Q2 2022.